Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Gelesis
About
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
- 101 - 250
Highlights
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- $31.50M
- Industries
- Biotechnology,Diabetes,Health Care,Medical Device
- Founded date
- Feb 1, 2006
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100 capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. Gelesis was founded in 2006 in Boston, Massachusetts
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 18, 2015 | Private Equity（PE） | $31.50M | 1 | — | — | Detail |
| Dec 26, 2006 | Series A | $500K | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Invesco
|
— | Private Equity（PE） |
|
|
— | Series A |
